Table 1.
Baseline characteristics of the patients
|
Characteristic
|
D-TACE-P-L group (n = 50)
|
C-TACE-P-L group (n = 54)
|
P value
|
| Sex, n (%) | 0.564 | ||
| Male | 42 (84.0) | 43 (79.6) | |
| Female | 8 (16.0) | 11 (20.4) | |
| Age (years), mean ± SD | 60.8 ± 9.2 | 62.2 ± 9.4 | 0.443 |
| ECOG PS, n (%) | 0.252 | ||
| 0 | 14 (28.0) | 10 (18.5) | |
| 1 | 36 (72.0) | 44 (81.5) | |
| Child-Pugh class, n (%) | 0.561 | ||
| A | 26 (52.0) | 25 (46.3) | |
| B | 24 (48.0) | 29 (53.7) | |
| BCLC, n (%) | 0.556 | ||
| B | 14 (28.0) | 18 (33.3) | |
| C | 36 (72.0) | 36 (66.7) | |
| AFP, n (%) | 0.727 | ||
| ≤ 400 ng/mL | 23 (46.0) | 23 (42.6) | |
| > 400 ng/mL | 27 (54.0) | 31 (57.4) | |
| Number of tumors, n (%) | 0.392 | ||
| ≤ 3 | 31 (62) | 29 (53.7) | |
| > 3 | 19 (38) | 25 (46.3) | |
| Largest tumor size (mm), mean ± SD | 96.3 ± 27.7 | 91.0 ± 36.7 | 0.324 |
| PVTT, n (%) | 0.873 | ||
| No | 23 (46.0) | 24 (44.4) | |
| Yes | 27 (54.0) | 30 (55.6) | |
| Hepatic vein invasion, n (%) | 0.656 | ||
| No | 38 (76.0) | 43 (20.4) | |
| Yes | 12 (24.0) | 11 (79.6) | |
| Extrahepatic metastasis, n (%) | 0.661 | ||
| No | 41 (82.0) | 46 (85.2) | |
| Yes | 9 (18.0) | 8 (14.8) | |
| Number of TACE, mean ± SD | 2.46 ± 1.0 | 2.56 ± 1.1 | 0.640 |
C-TACE-P-L: Conventional transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; D-TACE-P-L: Drug-eluting beads transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; ECOG PS: Eastern Cooperative Oncology Group Performance Status; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; PVTT: Portal vein tumor thrombus; TACE: Transarterial chemoembolization.